Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RPRX News 30 December 2025 - 8 January 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 08.01.2026

LIVEMarkets rolling coverageStarted: January 8, 2026, 12:00 AM ESTUpdated: January 8, 2026, 11:59 PM EST Royalty Pharma Undervalued on DCF Despite 1-Year Rally (RPRX) January 8, 2026, 11:59 PM EST. RPRX trades at $40.26, after a 40% return in the last year. A Discounted Cash Flow model-using a 2-stage Free Cash Flow to Equity framework-yields an intrinsic value around $179.83 a share, implying the stock is about 77.6% undervalued versus today. The model assumes TTM FCF of roughly $429.4 million and forecasts growth to about $4.2 billion by 2030. On a multiples basis, the stock trades at P/E 22.49x, above
8 January 2026
···
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology Index down about 1%. That matters now because smaller, cash-burning drug developers often move with risk appetite as much as on headlines. indexes.nasdaqomx.com Wall Street’s main indexes were largely muted as investors waited for minutes from the Federal Reserve’s December
30 December 2025
··

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
Go toTop